Dihydromyricetin may improve fatty liver disease by changing gut bacteria and inflammation signals

Dihydromyricetin (DHM) treatment significantly reduced serum levels of LPS, IL-1β, and TNF-α in mice with non-alcoholic fatty liver disease (NAFLD).

• NAFLD was induced in mice using a high-fat diet over 8 weeks.
• DHM treatment decreased liver expression of TLR4 and NF-κB p65.
• Intestinal flora analysis revealed an increase in beneficial bacteria, particularly in medium and high-dose groups.
• DHM treatment improved liver pathology by reducing fat deposition and inflammatory cell infiltration.
• Results suggest that DHM may prevent NAFLD progression by balancing gut microbiota and inhibiting inflammation.

Simplified